RIO DE JANEIRO, BRAZIL - "Is it Pfizer? Better yet," says the man in line at the Bom Retiro Basic Health Unit (UBS) in central São Paulo. "Yes, you see... I think we can trust Americans more than the others," he adds. If Caio Silveira, 34 years old, is not the rule, neither is he the exception in the race for the vaccine against Covid-19.
The distrust that leads to a preference for the North American pharmaceutical company's vaccine in relation to the Coronavac and Oxford/AstraZeneca's often stems from access to conflicting information about unwanted reactions . . .
To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed? Login Here